Takeaways included updates from the CheckMate 816 study, advances in technology, the role of metabolites and mobile CT screening in predicting cancer risk, and the importance of biomarkers for guiding optimal treatment. Read more
The combination treatment is the first and only regimen to show a survival benefit that surpasses the current standard of care for EGFR-mutated lung cancer. Read more
A new genetics study aims to collect data from 10,000 participants diagnosed with lung cancer to improve future outcomes and enhance research. Read more
FDA issues draft guidance on the use of AI for biological and drug product submissions, China’s NMPA grants priority review for the combination of savolitinib and osimertinib, and nivolumab and hyaluronidase-nvhy receive FDA approval for subcutaneous injection. Read more
During the opening plenary session at the 2024 Asia Conference on Lung Cancer, experts offered their perspectives on clinical trials, combination therapies, and research initiatives. Read more
Dr. Li said a considerable global burden of asbestos-related lung cancers and mesothelioma persists, even as beneficial impact of national asbestos bans are awaited. Read more
IASLC President-elect Caicun Zhou, MD, PhD, and CAALC Chair Chunxue Bai, MD, PhD, say the session provides an opportunity for colleagues from around the world to exchange ideas and learn from regional and cultural differences. Read more
Read an interview with Lilian Faroni, MD, MSc, PhD, who will discuss challenges of radiation oncology in Latin America. Read more
Projects—including a team science grant, an expanded IASLC Academy, and an international biomarker survey—aim to help the association meet the needs of the global lung cancer community, IASLC leaders say. Read more